

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



Lu, CH; Macdonald-Wallis, C; Gray, E; Pearce, N; Petzold, A; Norgren, N; Giovannoni, G; Fratta, P; Sidle, K; Fish, M; Orrell, R; Howard, R; Talbot, K; Greensmith, L; Kuhle, J; Turner, MR; Malaspina, A (2015) Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. *Neurology*, 84 (22). pp. 2247-57. ISSN 0028-3878 DOI: 10.1212/WNL.0000000000001642

Downloaded from: <http://researchonline.lshtm.ac.uk/2172636/>

DOI: [10.1212/WNL.0000000000001642](https://doi.org/10.1212/WNL.0000000000001642)

Usage Guidelines

Please refer to usage guidelines at <http://researchonline.lshtm.ac.uk/policies.html> or alternatively contact researchonline@lshtm.ac.uk.

Available under license: <http://creativecommons.org/licenses/by/2.5/>

Supplementary Table e-1. Demographic and clinical characteristics of the London and Oxford cohorts separately and combined.

n (%)		London-ALS (n=103)	Oxford-ALS (n=64)	Combined-ALS (n=167)	London-CTRL* [#] (n=42)	Oxford-CTRL* (n=36)	Combined-CTRL* [#] (n=78)
Gender	Male	66 (64%)	45 (70%)	112 (67%)	15 (35.7%)	15 (41.7%)	30 (38.5%)
	Female	37 (36%)	19 (30%)	56 (33%)	27 (64.3%)	21 (58.3%)	48 (61.5%)
Age of baseline sampling (years)	<60	32 (31%)	27 (42%)	59 (35.3%)	21 (50%)	24 (66.7%)	45 (57.7%)
	60-69	41 (40%)	25 (39%)	66 (39%)	11 (26%)	10 (27.8%)	21 (26.9%)
	70-79	20 (19.4%)	10 (16%)	30 (17.9%)	7 (16.7%)	2 (5.5%)	9 (11.5%)
	≥80	10 (9.6%)	2 (3%)	13 (7.8%)	1 (2.3%)	0	1 (1.3%)
Age of onset (years)	<60	36 (35%)	31 (48.4%)	67 (40%)			
	60-69	42 (40.7%)	25 (39%)	67(40%)			
	70-79	18 (17.5%)	7 (11%)	25 (15%)			
	≥80	7 (6.8%)	1 (1.6%)	9 (5%)			
Site of symptom onset	Limb	81 (78.6%)	51 (79.7%)	132 (79%)			
	Bulbar	20 (19.4%)	13 (20.3%)	33 (19.8%)			
	Both	2 (2%)	0	2 (1.2%)			
Diagnosis	Definite	19 (18.5%)	20 (31%)	39 (23%)			
	Probable	47 (45.6%)	21 (33%)	69 (41%)			
	Possible	27 (26.2%)	23 (36%)	50 (30%)			
	Laboratory-supported	10 (9.7%)	0	10 (6%)			
Diagnostic latency (months)	<12	55 (53.4%)	n/a	n/a			
	12-23	29 (28.2%)	n/a	n/a			
	24-35	10 (9.7%)	n/a	n/a			
	≥36	9 (8.7%)	n/a	n/a			
Duration to Baseline sampling (months)	<12	24 (23.3%)	9 (14%)	33 (19%)			
	12-23	32 (31.1%)	20 (31.3%)	52 (31%)			
	24-35	23 (22.3%)	14 (21.9%)	38 (23%)			
	≥36+	24 (23.3%)	21 (32.8%)	45 (27%)			
Ethnicity	Non-Caucasian	6 (5.8%)	0	6 (3.6%)			
C9orf72*	Positive case	3 (2.91%)	2 (3.1%)	5 (2.99%)			
ALSFRS_R*	47-40	37 (35.9%)	12 (18.8%)	49 (29.3%)			

score at baseline	39-26	52 (50.5%)	50 (78.1%)	102 (61.1%)			
	<=25	14 (13.6%)	2 (3.1%)	16 (9.6%)			
Progression rate at Baseline (PRB)	Fast: >1.0	22 (21.4%)	11 (17.2%)	33 (19.8%)			
	Intermediate: 0.5-1.0	30 (29.1%)	17 (26.6%)	47 (28.1%)			
	Slow: <0.5	51 (49.5%)	36 (56.2%)	87 (52.1%)			
Progression rate at the last visit (PRL)	Fast: >1.0	31 (30.1%)	15 (23.4%)	46 (27.5%)			
	Intermediate: 0.5-1.0	29 (28.2%)	18 (28.2%)	47 (28.2%)			
	Slow: <0.5	43 (41.7%)	31 (48.4%)	74 (44.3%)			
Riluzole Treatment	With	74 (71.8%)	30 (46.9%)	104 (62.3%)			
	without	29 (28.2%)	34 (53.1%)	63 (37.7%)			

*: CTRL: controls; C9orf72: chromosome 9 open reading frame 72; ALSFRS_R: ALS

functional rating scale-revised; #: date of birth from two controls was not available.

Information for diagnostic latency was not available in Oxford cohort.